Skip to content

Study · Observational study · n = 113 · 2024

4 results

Weighing your options-intragastric balloon versus semaglutide.

Choy K, Abbitt D, Kovar A, Jones TS, McCallum M, Thomas EA, Saxon DR, Wikiel KJ, Jones EL

Surgical endoscopy13 Aug 2024Cited by 3 (Europe PMC)

PMID39138683 (opens in a new tab)DOI10.1007/s00464-024-11169-z (opens in a new tab)PepBankPUB-39138683
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Veterans with obesity, semaglutide produced less weight loss at 0-3 months than intragastric balloon (-5.1 kg versus -11.8 kg).

    In plain wordsIn Veterans with obesity, semaglutide gave less weight loss in the first 3 months than the intragastric balloon.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight change 0-3 months
    Study

    n = 113

    Comparator
    Intragastric balloon
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change 0-3 months
    −5.1 kg
    semaglutide
    Weight change 0-3 months
    −11.8 kg
    intragastric balloon

    Source sentences

    Summary
    Weight (kg) change was measured at intervals: 0-3 months:- 11.8(- 17,- 9.5) IGB vs. - 5.1(- 7.4,- 2.3) semaglutide, p < 0.0001; 0-6 months:- 12.7(- 18.4,- 9.9) vs. - 9.4(- 12.6,- 6.1), p = 0.03; 3-6 months:- 0.5(- 2.3,2.3) vs. - 4.3(- 6.8,- 1.6), p < 0.0001; 6-12 months:3(0,7.3) vs. - 1.9(- 4.7,1), p = 0.0006.
    2 context sentences
    Summary · context
    Retrospective review of prospective databases of perioperatively placed intragastric balloon cohort from 1/2019-1/2023 compared to patients who received initiatory GLP1RA from 6/2021-8/2022 at a VA Medical Center(VAMC).
    Summary · context
    Seventeen (15%) patients underwent IGB placement and 96 (85%) patients received semaglutide.
  2. 02HumanObservational studyEfficacy outcome

    In Veterans with obesity, semaglutide produced less weight loss at 0-6 months than intragastric balloon (-9.4 kg versus -12.7 kg).

    In plain wordsIn Veterans with obesity, semaglutide gave less weight loss in the first 6 months than the intragastric balloon.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight change 0-6 months
    Study

    n = 113

    Comparator
    Intragastric balloon
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change 0-6 months
    −9.4 kg
    semaglutide
    Weight change 0-6 months
    −12.7 kg
    intragastric balloon

    Source sentences

    Summary
    Weight (kg) change was measured at intervals: 0-3 months:- 11.8(- 17,- 9.5) IGB vs. - 5.1(- 7.4,- 2.3) semaglutide, p < 0.0001; 0-6 months:- 12.7(- 18.4,- 9.9) vs. - 9.4(- 12.6,- 6.1), p = 0.03; 3-6 months:- 0.5(- 2.3,2.3) vs. - 4.3(- 6.8,- 1.6), p < 0.0001; 6-12 months:3(0,7.3) vs. - 1.9(- 4.7,1), p = 0.0006.
    2 context sentences
    Summary · context
    Retrospective review of prospective databases of perioperatively placed intragastric balloon cohort from 1/2019-1/2023 compared to patients who received initiatory GLP1RA from 6/2021-8/2022 at a VA Medical Center(VAMC).
    Summary · context
    Seventeen (15%) patients underwent IGB placement and 96 (85%) patients received semaglutide.
  3. 03HumanObservational studyEfficacy outcome

    In Veterans with obesity, semaglutide produced more weight loss at 3-6 months than intragastric balloon (-4.3 kg versus -0.5 kg).

    In plain wordsIn Veterans with obesity, semaglutide gave more weight loss between months 3 and 6 than the intragastric balloon.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight change 3-6 months
    Study

    n = 113

    Comparator
    Intragastric balloon
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change 3-6 months
    −4.3 kg
    semaglutide
    Weight change 3-6 months
    −0.5 kg
    intragastric balloon

    Source sentences

    Summary
    Weight (kg) change was measured at intervals: 0-3 months:- 11.8(- 17,- 9.5) IGB vs. - 5.1(- 7.4,- 2.3) semaglutide, p < 0.0001; 0-6 months:- 12.7(- 18.4,- 9.9) vs. - 9.4(- 12.6,- 6.1), p = 0.03; 3-6 months:- 0.5(- 2.3,2.3) vs. - 4.3(- 6.8,- 1.6), p < 0.0001; 6-12 months:3(0,7.3) vs. - 1.9(- 4.7,1), p = 0.0006.
    2 context sentences
    Summary · context
    Retrospective review of prospective databases of perioperatively placed intragastric balloon cohort from 1/2019-1/2023 compared to patients who received initiatory GLP1RA from 6/2021-8/2022 at a VA Medical Center(VAMC).
    Summary · context
    Seventeen (15%) patients underwent IGB placement and 96 (85%) patients received semaglutide.
  4. 04HumanObservational studyEfficacy outcome

    In Veterans with obesity, weight fell by 1.9 kg with semaglutide at 6-12 months, whereas it rose by 3 kg after intragastric balloon.

    In plain wordsIn Veterans with obesity, weight kept falling with semaglutide between months 6 and 12, whereas weight rose after the intragastric balloon.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight change 6-12 months
    Study

    n = 113

    Comparator
    Intragastric balloon
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change 6-12 months
    −1.9 kg
    semaglutide
    Weight change 6-12 months
    3 kg
    intragastric balloon

    Source sentences

    Summary
    Weight (kg) change was measured at intervals: 0-3 months:- 11.8(- 17,- 9.5) IGB vs. - 5.1(- 7.4,- 2.3) semaglutide, p < 0.0001; 0-6 months:- 12.7(- 18.4,- 9.9) vs. - 9.4(- 12.6,- 6.1), p = 0.03; 3-6 months:- 0.5(- 2.3,2.3) vs. - 4.3(- 6.8,- 1.6), p < 0.0001; 6-12 months:3(0,7.3) vs. - 1.9(- 4.7,1), p = 0.0006.
    2 context sentences
    Summary · context
    Retrospective review of prospective databases of perioperatively placed intragastric balloon cohort from 1/2019-1/2023 compared to patients who received initiatory GLP1RA from 6/2021-8/2022 at a VA Medical Center(VAMC).
    Summary · context
    Seventeen (15%) patients underwent IGB placement and 96 (85%) patients received semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.